首页 | 本学科首页   官方微博 | 高级检索  
检索        

关注抗血管内皮生长因子药物治疗眼部新生血管疾病的潜在风险
引用本文:张卯年.关注抗血管内皮生长因子药物治疗眼部新生血管疾病的潜在风险[J].中华眼底病杂志,2010,26(1):2-5.
作者姓名:张卯年
作者单位:解放军总医院眼科解放军眼科中心,北京,100853
摘    要:抗血管内皮生长因子(VEGF)药物为眼部新生血管疾病的治疗开辟了新的途径,其有效性和安全性也已经为大量研究工作所证实。但在临床实践中,长期、大剂量的应用抗VEGF药物同时也会带来一些新的问题和并发症,甚至会影响正常眼组织血管生成过程和视网膜的血液供应。因此,必须重视过度抗VEGF治疗眼部新生血管疾病带来的问题和潜在风险。

关 键 词:脉络膜新生血管化/药物疗法  视网膜新生血管化/药物疗法  抗体    单克隆/治疗应用  抗体    单克隆/副作用  血管内皮生长因子类
收稿时间:2008-08-05

Pay attention to the potential risks of anti-vascular endothelial growth factor therapy for neovascular disease
ZHANG Mao-nian.Pay attention to the potential risks of anti-vascular endothelial growth factor therapy for neovascular disease[J].Chinese Journal of Ocular Fundus Diseases,2010,26(1):2-5.
Authors:ZHANG Mao-nian
Abstract:Anti-vascular dndothelial growth factor (VEGF) drugs have open up a new treatment channel for ocular neovascular diseases. A lots of clinical data has proved that anti-VEGF drugs are effective and safe. But we should also notice that long-term and excessive usage of anti-VEGF drugs brings some new problems and complications, and even affect the normal ocular physiological process of the angiogenesis and retinal blood flow. So, it is necessary to pay attention to the problems and potential risks of excessive usage of anti-VEGF therapies for ocular neovascular disease.
Keywords:horoidal neovascularization/drug therapy  Retinal neovascularization/ drug therapy  Antibodies  monoclonal/ therapeutic use  Antibodies  monoclonal/ adverse effects  Vascular endothelial growth factors
本文献已被 万方数据 等数据库收录!
点击此处可从《中华眼底病杂志》浏览原始摘要信息
点击此处可从《中华眼底病杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号